Home›Screener›AGEN›Profile
C
63/100

Agenus Inc

AGENImmuno-Oncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Agenus Inc (AGEN) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 2[1], 1 Phase 1[2].

AGEN has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001098972 (2026-04-11) ↗
🏛
Upcoming Catalysts
botensilimab + balstilimab — recurrent/metastatic cervical cancer
2026-09-10
in 98d
🔬
Clinical Trials
4
NCT03860272Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05529316Advanced Melanoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05608044Metastatic Colorectal Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05630183Metastatic Pancreatic Ductal Adenocarcinoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
3 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates1
Insider Filings1
Clinical Trials1
Sector Peers (Immuno-Oncology)
CLDXCelldex Therapeutics
C
JANXJanux Therapeutics
D
RCUSArcus Biosciences
D
ARQTArcus Biosciences
F
Data Provenance
cik1 verified
clinical trial4 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR